* GENOSAFE *
2003 - IDF
Évry
(near Paris)
www.genosafe.com Contract, Services
Key words: Bio-therapeutics, Drug evaluation
Mission: to evaluate the efficacy and safety of biotherapeutic products (viral and non-viral vectors, vaccines, recombinant proteins, monoclonal antibodies, cellular products …), for third parties
Clients: Pharmaceutical industry, Biotechs, Research labs
contact@genosafe.com
Age: 6 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS | | Start-up |
Managing Dir.-CEO: Caizergues (Didier) [born 1958, Pharm.D., ex-Synthelabo, Abbott, Genethon]
Sc.Dir.-CSO: Audit (Muriel) [Ph.D. Biology, ex-Genethon]
Fin.Dir.-CFO:
BusDev: Zuliani (Vincent) [Ms. microbiology, ex-Genethon]
Financers (Hist.): A2I (seed), Genethon, AFM | Turnover (M€) : 0.71 (2008), 0.37 (2006)
Total funding (M€) : 3.5
Last funding (M€) : 3.5
Focus : Multiple
Position : Subcontractor
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME | | 2008 .11 | Nomination : Didier Caizergues as Board President and CEO, replacing Anne-Marie Masquelier | ORGN | [5 years] |
| 2006 .11 | Financing : grant of 3.5 M€, by A2i (Oseo), coordinated by Mérieux Alliance, within ADNA project | DEBT | [3 years] |
| 2005 .06 | Nomination : Anne-Marie Masquelier, as CEO (plus, President, in 2006) | ORGN | [1 year] |
| 2003 .09 | Company founded by Genethon and AFM (Association Française pour les Myopathies, i.e. French Muscular Dystrophy Association) | ORGF | [0 year] | Actualisation / Updating: 09-Apr-2009 |
|
